Statisticians in European regulatory agencies.
The UK body of statisticians in the pharmaceutical industry, PSI, has called on heads of European regulatory agencies responsible for assessing applications for marketing authorizations for new medicines in the EU to employ full time statisticians. In order to assess the present situation a survey has been conducted to identify the number of agencies employing one or more full time statisticians. Out of 29 responding agencies, 12 employed one or more statisticians on a full time basis, whereas 17 did not. Among these 17, 7 involved external experts on a regular basis, 5 involved external statisticians on a case-by-case basis, whereas 5 never involved external statistical expertise. Failure to involve statisticians in the assessment of efficacy and safety of medicines does not automatically lead to reports of low quality or invalid assessment of benefit-risk. However, in depth knowledge of statistical methodology is often necessary to uncover weaknesses and potentially biased efficacy estimates. This might be of importance for the final opinion on granting a marketing authorization, and statistical review should therefore be conducted by those who are professionally expert in the area. A positive trend toward an increased involvement of statistical expertise in the European network of regulatory agencies is observed.
Skovlund
Eva
E
Norwegian Medicines Agency, Oslo, Norway. eva.skovlund@noma.no
D017277:Drug Approval / Q000379:methods* / Q000706:statistics & numerical data*; D004335:Drug and Narcotic Control / Q000379:methods*; D005062:European Union / Q000706:statistics & numerical data*; D006077:Government Agencies / Q000458:organization & administration*; D006801:Humans